There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PepGen Inc. (PEPG – Research Report), 4D Molecular Therapeutics (FDMT – Research Report) and Compass Therapeutics (CMPX – Research Report) with bullish sentiments.
PepGen Inc. (PEPG)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on PepGen Inc. on November 9 and set a price target of $22.00. The company’s shares closed last Monday at $4.34, close to its 52-week low of $3.72.
According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
PepGen Inc. has an analyst consensus of Strong Buy, with a price target consensus of $22.75, which is a 492.4% upside from current levels. In a report issued on November 8, Wedbush also maintained a Buy rating on the stock with a $21.00 price target.
See the top stocks recommended by analysts >>
4D Molecular Therapeutics (FDMT)
In a report issued on November 9, Mani Foroohar from Leerink Partners maintained a Buy rating on 4D Molecular Therapeutics, with a price target of $25.00. The company’s shares closed last Monday at $10.53, close to its 52-week low of $8.57.
According to TipRanks.com, Foroohar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on 4D Molecular Therapeutics is a Strong Buy with an average price target of $33.17, which is a 199.9% upside from current levels. In a report issued on October 26, RBC Capital also initiated coverage with a Buy rating on the stock with a $25.00 price target.
Compass Therapeutics (CMPX)
Leerink Partners analyst Andrew Berens reiterated a Buy rating on Compass Therapeutics on November 9 and set a price target of $11.00. The company’s shares closed last Monday at $1.40.
According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of
Compass Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, which is a 577.4% upside from current levels. In a report issued on November 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PEPG:
- PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- PepGen reports Q3 EPS (98c), consensus (88c)
- PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
- PepGen announces FDA lifted clinical hold on its IND for FREEDOM-DM1
- PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
